Refractory multiple myeloma is myeloma that has stopped responding to treatment or progresses within 60 days of completing therapy. Unlike relapsed myeloma, where the cancer returns after a period of remission, refractory disease means the current treatment is no longer working. Nearly all myeloma patients will eventually face one or both of these situations over the course of their disease.
How Refractory Differs From Relapsed
The distinction matters because it changes what happens next. Relapsed myeloma means the cancer responded to treatment initially but came back later, sometimes months or years down the line. Refractory myeloma means the cancer either never responded meaningfully (less than a 25% reduction in disease markers) or started growing again while the patient was still on treatment or within 60 days of finishing it.
Some patients have what’s called relapsed-and-refractory disease, meaning their cancer came back after an earlier remission and then stopped responding to the next round of treatment. This is the most common scenario for patients who have cycled through several lines of therapy.
Why Myeloma Stops Responding
Myeloma cells aren’t a single uniform population. They’re a diverse collection of subgroups, and treatment acts like a filter. Sensitive cells die off, but resistant ones survive and multiply. Single-cell sequencing research has identified three patterns: in patients who reach deep remission, the cancerous cells are effectively eliminated. In those who don’t, the surviving cells either hold steady or actively outcompete their neighbors through a process called clonal selection.
The surviving cells develop several tricks. Some shift their energy metabolism toward burning fatty acids rather than the usual fuel sources, which helps them endure the stress of treatment. Others ramp up anti-cell-death pathways, particularly one called NF-κB, which essentially makes the cell harder to kill. Resistant cells also overexpress proteins that help them manage the internal stress caused by chemotherapy, allowing them to fold proteins correctly even under harsh conditions.
Perhaps most importantly, the most treatment-resistant myeloma cells learn to manipulate the immune system around them. They increase surface proteins that send “stand down” signals to natural killer cells and other immune cells that would normally attack them. This immune evasion is a major reason why the disease becomes harder to control with each successive treatment line.
How Progression Is Detected
Doctors track myeloma by measuring abnormal proteins the cancer produces. Progression is typically defined as a 25% increase from the lowest confirmed level in one or more markers: a rise in the M-protein in blood of at least 0.5 g/dL, or at least 1 g/dL if the baseline was already high (5 g/dL or above), or an increase in abnormal protein in the urine to 200 mg or more over 24 hours. Rising numbers on routine blood work are often the first sign that a treatment is losing its grip, sometimes before symptoms appear.
Triple-Class and Heavily Pretreated Disease
Myeloma treatment relies on three main drug classes: proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. Most patients receive all three over the course of their treatment. When myeloma becomes refractory to drugs from all three classes, it’s called triple-class refractory disease. This is a particularly challenging situation because the standard backbone therapies have all been exhausted.
Triple-class refractory patients have grown steadily as a population in recent years, largely because the same three drug classes are now used earlier and in combination. The good news is that newer treatment approaches target the cancer through entirely different mechanisms.
CAR-T Cell Therapy
CAR-T therapy involves collecting a patient’s own immune cells, engineering them in a lab to recognize a protein on myeloma cells called BCMA, and infusing them back. Two CAR-T products are approved for myeloma that has progressed after multiple prior treatments.
Results from the CARTITUDE-1 trial, which studied one of these therapies (ciltacabtagene autoleucel) in heavily pretreated patients, showed a median overall survival of about 60.7 months. At the five-year mark, a third of patients remained in remission without needing additional treatment. These are striking numbers for a population that historically had survival measured in months rather than years. In smaller studies where patients received a second CAR-T product after relapsing from the first, response rates reached 100%, with 70% achieving complete responses both times.
The treatment requires a one-time infusion but involves a manufacturing wait (typically several weeks while the cells are engineered), a short course of chemotherapy to prepare the body, and close monitoring afterward for side effects.
Bispecific Antibodies
Bispecific antibodies are off-the-shelf drugs that grab onto both a myeloma cell and an immune T cell, forcing them together so the T cell can kill the cancer. Several are now approved for patients who have been exposed to all three standard drug classes.
Teclistamab targets BCMA (the same protein as CAR-T), while talquetamab targets a different protein called GPRC5D. In clinical trials, combining both antibodies together produced responses in about 79% to 80% of patients, with roughly half achieving complete responses. Having two different targets matters because if the cancer loses one protein from its surface to escape treatment, the other drug can still find it.
A newer bispecific antibody, linvoseltamab, received FDA approval in mid-2024 and has been added as a preferred treatment option in national guidelines for relapsed or refractory disease.
Side Effects of Newer Immunotherapies
Both CAR-T therapy and bispecific antibodies can trigger cytokine release syndrome (CRS), an inflammatory reaction that occurs when large numbers of immune cells activate at once. Symptoms range from fever and chills to drops in blood pressure in more severe cases. With talquetamab, CRS occurred in about 72% of patients, mostly during the initial dosing phase. The vast majority of these episodes were mild and resolved within two hours of intervention.
A less common but more concerning side effect is neurotoxicity, which can cause confusion, difficulty speaking, or tremors. This occurred in about 6% of patients receiving talquetamab, and cases were mild to moderate. For both side effects, there are established protocols that make them manageable when patients are monitored appropriately during the early treatment period.
Bispecific antibodies also carry a risk of infections because they affect normal immune function. Talquetamab in particular can cause taste changes and skin and nail changes due to its GPRC5D target being present on some normal tissues. These side effects are distinctive but generally manageable.
Newer Drugs in Development
A class of oral drugs called CELMoDs represents the next evolution of immunomodulatory therapy. These drugs work through the same basic mechanism as older immunomodulatory agents but are specifically optimized for stronger myeloma cell killing and greater immune activation. Mezigdomide, one of the most advanced in this class, showed statistically significant improvement in progression-free survival when combined with a proteasome inhibitor in a phase 3 trial, compared to the proteasome inhibitor alone. These drugs are particularly important for refractory patients because they can overcome resistance to the older immunomodulatory drugs that the cancer has already learned to evade.